March 18, 2015
Via EDGAR
Bryan J. Pitko
Attorney-Advisor
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street NE
Washington, DC 20549
Re: Green Meadow Products, Inc.
Amendment No. 4 to Registration Statement on Form S-1
Filed March 19, 2015
File No. 333-198993
Dear Bryan J Pitko:
This isGreen Meadow Products, Inc.'s (the Company) response to your correspondence dated February 26, 2015 relating to the Company's Registration Statement on Form S-1 filed on September 29, 2014. For ease of reference, each of the Staff's comments is reproduced below, followed by our response.
General
1. We note your response to prior comment 1. Please expand the disclosure in your prospectus summary, risk factors, and regulatory section to acknowledge that the FDA may classify your product as a drug specifically because of your statements that your product may be used for pain relief made in your effort to market or sell your product.
Response
We have amended the prospectus summary (P. 5), risk factors (P.10), businnes description (P.17)and regulatory section (P.20)to acknowledge that the FDA may classify our product as a drug specifically because of our statements that our product may be used for pain relief made in our effort to market or sell our product.
2. Please update your financial statements and related financial information in accordance with the requirements set forth in Rule 8-08 of Regulation S-X.
Response
We have updated our financial statements and related financial information accordingly.
Sincerely,
/s/Stan Windhorn
President, Green Meadow Products, Inc.
